Biotechnology company Psilera Inc and organ-on-a-chip technology specialist Hesperos Inc announced on Monday a strategic agreement to accelerate the preclinical development of Psilera's lead compound, PSIL-006, targeting frontotemporal dementia (FTD).

The partnership is intended to leverage Hesperos' proprietary Human-on-a-Chip platform, which integrates patient-derived induced pluripotent stem cells (iPSCs) into interconnected, multi-organ systems. This advanced modelling approach is claimed to enable precise evaluation of drug efficacy and safety, recently promoted by the FDA to reduce reliance on animal testing and expedite clinic-ready datasets.

Hesperos says that its platform has been recognised for its ability to replicate human physiological responses, providing valuable data on drug interactions across multiple organ systems. The platform has supported multiple Investigational New Drug (IND) and Orphan Drug Designation (ODD) applications.

FTD is a progressive neurodegenerative disorder with limited treatment options. The integration of next-generation neuroplastogen, PSIL-006, with Hesperos' advanced biological platform is intended to develop targeted treatments to address this unmet medical need.

Results from Psilera's preclinical modelling are expected in Q3 2025.